Skip to main content
SpringerLink
Log in

Viral Hepatitis in Elderly Haemodialysis Patients

Current Prevention and Management Strategies

  • Review Article
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Viral hepatitis continues to be a relevant topic for haemodialysis centres, although the number of infected dialysis patients is declining in most countries. Chronic hepatitis B and C lead to detrimental complications such as liver cirrhosis and hepatocellular carcinoma. These complications can be avoided by successful antiviral treatment. In individuals with normal renal function, drug therapy of chronic hepatitis B is evolving quickly. Today there are several options but no agreed standard therapy. In the absence of renal failure, chronic hepatitis C should be treated with a combination of pegylated interferon-α and ribavirin. For both infections, there is no general indication to treat all patients; several criteria can be used to predict benefits and downsides.

Chronic renal failure severely alters immune function, particularly activation of T lymphocytes and cytokine production by mononuclear cells. Aging further influences the immune system with deviation of T-lymphocyte differentiation. Both effects seem to act additively, leaving the elderly haemodialysis patient with extensive immune dysfunction. While these effects do not put the patient at risk of opportunistic infection, they do have a relevant effect on the clinical course of viral hepatitis.

Haemodialysis patients infected with hepatitis B manifest a subclinical, often anicteric disease, and at least 60% of the infections become chronic. These patients usually do not fulfil the criteria for successful antiviral treatment, since they have normal or slightly elevated liver enzyme levels and few histological signs of liver inflammation. In addition, the prognosis in terms of cirrhosis and hepatocellular carcinoma might be more favourable than in individuals with normal renal function. The former standard treatment of chronic hepatitis B with interferon-α or its derivate pegylated interferon was badly tolerated in dialysis patients and associated with low efficacy. Indeed, prior to the advent of nucleoside analogues there was a clear recommendation not to treat chronic hepatitis B infection in all except a few dialysis patients. However, the newer treatment options appear to work well. In particular, there is growing evidence for the effectiveness and tolerability of lamivudine in dialysis patients, including the elderly. Use of adefovir and entecavir has also been reported in a few cases. At present, while we still do not recommend treatment, therapy with nucleoside analogues might be an option in selected patients, for example, those planning renal transplantation. The major effort against hepatitis B should be directed at vaccination and hygienic precautions to prevent the infection.

Treatment of hepatitis C in patients undergoing haemodialysis is also limited by the poor tolerability of interferons. Ribavirin is contraindicated because of severe haemolytic anaemia, although a few studies have attempted to manage this with administration of high doses of erythropoetin. Those patients who complete the full course of interferon therapy may expect sustained viral responses comparable with healthy individuals, but in most trials, 30–50% of patients were forced to interrupt treatment because of adverse effects. There is no general indication to treat chronic hepatitis C in haemodialysis patients. Arguments in favour of treatment include elevated liver enzymes, histological signs of relevant liver inflammation, younger age, a virus genotype other than 1 and planned renal transplantation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Table I

Similar content being viewed by others

References

  1. Liaw YF, Leung N, Guan R, et al. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2005 update. Liver Int 2005 Jun; 25(3): 472–89

    Article  PubMed  Google Scholar 

  2. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2007 Feb; 45(2): 507–39

    Article  PubMed  CAS  Google Scholar 

  3. NIH consensus statement on management of hepatitis C: 2002. NIH Consens State Sci Statements 2002 Jun 10; 19(3): 1–46

    Google Scholar 

  4. McCaughan GW, Omata M, Amarapurkar D, et al. Asian Pacific Association for the Study of the Liver consensus statements on the diagnosis, management and treatment of hepatitis C virus infection. J Gastroenterol Hepatol 2007 May; 22(5): 615–33

    Article  PubMed  CAS  Google Scholar 

  5. Dianzani F. Biological basis for the clinical use of interferon. Gut 1993; 34 (2 Suppl.): S74–6

    Article  PubMed  CAS  Google Scholar 

  6. Rostaing L, Modesto A, Baron E, et al. Acute renal failure in kidney transplant patients treated with interferon alpha 2b for chronic hepatitis C. Nephron 1996; 74(3): 512–6

    Article  PubMed  CAS  Google Scholar 

  7. Wong DK, Cheung AM, O’Rourke K, et al. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. Ann Intern Med 1993 Aug 15; 119(4): 312–23

    PubMed  CAS  Google Scholar 

  8. Brook MG, Karayiannis P, Thomas HC. Which patients with chronic hepatitis B virus infection will respond to alpha-interferon therapy? A statistical analysis of predictive factors. Hepatology 1989 Nov; 10(5): 761–3

    Article  PubMed  CAS  Google Scholar 

  9. Flink HJ, van Zonneveld M, Hansen BE, et al. Treatment with peg-interferon alpha-2b for HBeAg-positive chronic hepatitis B: HBsAg loss is associated with HBV genotype. Am J Gastroenterol 2006 Feb; 101(2): 297–303

    Article  PubMed  CAS  Google Scholar 

  10. Dienstag JL, Schiff ER, Wright TL, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 1999 Oct 21; 341(17): 1256–63

    Article  PubMed  CAS  Google Scholar 

  11. Kawaoka T, Suzuki F, Akuta N, et al. Efficacy of lamivudine therapy in elderly patients with chronic hepatitis B infection. J Gastroenterol 2007 May; 42(5): 395–401

    Article  PubMed  CAS  Google Scholar 

  12. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 Dec; 125(6): 1714–22

    Article  PubMed  CAS  Google Scholar 

  13. Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000 Apr; 46(4): 562–8

    Article  PubMed  CAS  Google Scholar 

  14. Rudin D, Shah SM, Kiss A, et al. Interferon and lamivudine vs. interferon for hepatitis B e antigen-positive hepatitis B treatment: meta-analysis of randomized controlled trials. Liver Int 2007 Nov; 27(9): 1185–93

    Article  PubMed  CAS  Google Scholar 

  15. Marcellin P, Chang TT, Lim SG, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med 2003 Feb 27; 348(9): 808–16

    Article  PubMed  CAS  Google Scholar 

  16. Chang TT, Gish RG, de Man R, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1001–10

    Article  PubMed  CAS  Google Scholar 

  17. Lai CL, Shouval D, Lok AS, et al. Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2006 Mar 9; 354(10): 1011–20

    Article  PubMed  CAS  Google Scholar 

  18. Song BC, Suh DJ, Lee HC, et al. Which patients with chronic hepatitis B are more likely to relapse after interferon alpha-induced hepatitis B e antigen loss in Korea? J Clin Gastroenterol 2004 Feb; 38(2): 124–9

    Article  PubMed  CAS  Google Scholar 

  19. Manns MP, McHutchison JG, Gordon SC, et al. Peg-interferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001 Sep 22; 358(9286): 958–65

    Article  PubMed  CAS  Google Scholar 

  20. Fried MW, Shiftman ML, Reddy KR, et al. Peg-interferon alfa2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 Sep 26; 347(13): 975–82

    Article  PubMed  CAS  Google Scholar 

  21. Hadziyannis SJ, Sette Jr H, Morgan TR, et al. Peg-interferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 Mar 2; 140(5): 346–55

    PubMed  CAS  Google Scholar 

  22. Martinot-Peignoux M, Marcellin P, Pouteau M, et al. Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995 Oct; 22 (4 Pt 1): 1050–6

    Article  PubMed  CAS  Google Scholar 

  23. Conjeevaram HS, Everhart JE, Hoofnagle JH. Predictors of a sustained beneficial response to interferon alfa therapy in chronic hepatitis C. Hepatology 1995 Oct; 22 (4 Pt 1): 1326–9

    Article  PubMed  CAS  Google Scholar 

  24. Strader DB, Wright T, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 Apr; 39(4): 1147–71

    Article  PubMed  Google Scholar 

  25. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C. Intervirology 2007; 50(1): 16–23

    Article  PubMed  CAS  Google Scholar 

  26. Thabut D, Le CS, Thibault V, et al. Hepatitis C in 6,865 patients 65 yr or older: a severe and neglected curable disease? Am J Gastroenterol 2006 Jun; 101(6): 1260–7

    Article  PubMed  Google Scholar 

  27. Bresci G, Del CL, Romanelli AM, et al. The use of recombinant interferon alfa-2b in elderly patients with anti-HCV-positive chronic active hepatitis. J Am Geriatr Soc 1993 Aug; 41(8): 857–62

    PubMed  CAS  Google Scholar 

  28. Horiike N, Masumoto T, Nakanishi K, et al. Interferon therapy for patients more than 60 years of age with chronic hepatitis C. J Gastroenterol Hepatol 1995 May; 10(3): 246–9

    Article  PubMed  CAS  Google Scholar 

  29. Honda T, Katano Y, Urano F, et al. Efficacy of ribavirin plus interferon-alpha in patients aged ≥60 years with chronic hepatitis C. J Gastroenterol Hepatol 2007 Jul; 22(7): 989–95

    Article  PubMed  CAS  Google Scholar 

  30. Floreani A, Minola E, Carderi I, et al. Are elderly patients poor candidates for pegylated interferon plus ribavirin in the treatment of chronic hepatitis C? J Am Geriatr Soc 2006 Mar; 54(3): 549–50

    Article  PubMed  Google Scholar 

  31. Ruiz P, Gomez F, Schreiber AD. Impaired function of macrophage Fcg receptors in end-stage renal disease. N Engl J Med 1990; 322: 717–22

    Article  PubMed  CAS  Google Scholar 

  32. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: central factors in the altered cytokine network of uremia — the good, the bad, and the ugly. Kidney Int 2005 Apr; 67(4): 1216–33

    Article  PubMed  CAS  Google Scholar 

  33. Girndt M, Köhler H, Schiedhelm-Weick E, et al. T-cell activation defect in hemodialysis patients: evidence for a role of the B7/CD28 pathway. Kidney Int 1993; 44: 359–65

    Article  PubMed  CAS  Google Scholar 

  34. London WT, DiFiglia M, Sutnick AI, et al. An epidemic of hepatitis in a chronic hemodialysis unit. N Engl J Med 1969; 281: 571–8

    Article  PubMed  CAS  Google Scholar 

  35. Crosnier J, Jungers P, Couroucé AM, et al. Randomized placebo-controlled trial of hepatitis B surface antigen vaccine in French hemodialysis units: II. Hemodialysis patients. Lancet 1981; I: 797–800

    Article  Google Scholar 

  36. Meuer SC, Hauer M, Kurz P, et al. Selective blockade of the antigen-receptor-mediated pathway of T cell activation in patients with impaired immune responses. J Clin Invest 1987; 80: 743–9

    Article  PubMed  CAS  Google Scholar 

  37. Meuer SC, Dumann H, Meyer zum Büschenfelde KH, et al. Low dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1989; I: 15–8

    Article  Google Scholar 

  38. Liu Y, Janeway CA. Cells that present both specific ligand and costimulatory activity are the most efficient inducers of clonal expansion of normal CD4 T cells. Proc Natl Acad Sci U S A 1992; 89: 3845–9

    Article  PubMed  CAS  Google Scholar 

  39. McAdam AJ, Schweitzer AN, Sharpe AH. The role of B7 costimulation in activation and differentiation of CD4+ and CD8+ T cells. Immunol Rev 1998; 165: 231–47

    Article  PubMed  CAS  Google Scholar 

  40. Schweitzer AN, Sharpe AH. Studies using antigen-presenting cells lacking expression of both B7-1 (CD80) and B7-2 (CD86) show distinct requirements for B7 molecules during priming versus restimulation of Th2 but not Th1 cytokine production. J Immunol 1998; 161: 2762–71

    PubMed  CAS  Google Scholar 

  41. Beaman M, Michael J, MacLennan IC, et al. T-cell-independent and T-cell-dependent antibody responses in patients with chronic renal failure. Nephrol Dial Transplant 1989; 4: 216–21

    PubMed  CAS  Google Scholar 

  42. Girndt M, Sester M, Sester U, et al. Defective expression of B7-2 (CD86) on monocytes of dialysis patients correlates to the uremia-associated immune defect. Kidney Int 2001 Apr; 59(4): 1382–9

    Article  PubMed  CAS  Google Scholar 

  43. Girndt M, Sester U, Kaul H, et al. Production of proinflammatory and regulatory monokines in hemodialysis patients shown at a single cell level. J Am Soc Nephrol 1998; 9: 1689–96

    PubMed  CAS  Google Scholar 

  44. Stenvinkel P, Heimbürger O, Paultre F, et al. Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 1999; 55: 1899–911

    Article  PubMed  CAS  Google Scholar 

  45. Girndt M, Köhler H, Schiedhelm Weick E, et al. Production of interleukin-6, tumor necrosis factor alpha and interleukin-10 in vitro correlates with the clinical immune defect in chronic hemodialysis patients. Kidney Int 1995; 47: 559–65

    Article  PubMed  CAS  Google Scholar 

  46. Sester U, Sester M, Hauk M, et al. T-cell activation follows Th1 rather than Th2 pattern in haemodialysis patients. Nephrol Dial Transplant 2000; 15: 1217–23

    Article  PubMed  CAS  Google Scholar 

  47. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997 Jun; 18(6): 263–6

    Article  PubMed  CAS  Google Scholar 

  48. Dinits-Pensy M, Forrest GN, Cross AS, et al. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005 Dec; 46(6): 997–1011

    Article  PubMed  Google Scholar 

  49. Pillion G, Chiesa M, Maisin A, et al. Immunogenicity of hepatitis B vaccine (HEVAC B) in children with advanced renal failure. Pediatr Nephrol 1990; 4: 627–9

    Article  PubMed  CAS  Google Scholar 

  50. Gershon AA. Immunizations for pediatric transplant patients. Kidney Int 1993; 44Suppl. 43: S87–90

    Google Scholar 

  51. Flynn JT, Frisch K, Kershaw DB, et al. Response to early measles-mumps-rubella vaccination in infants with chronic renal failure and/or receiving peritoneal dialysis. Adv Perit Dial 1999; 15: 269–72

    PubMed  CAS  Google Scholar 

  52. Castle SC. Clinical relevance of age-related immune dysfunction. Clin Infect Dis 2000 Aug; 31(2): 578–85

    Article  PubMed  CAS  Google Scholar 

  53. Bernstein E, Kaye D, Abrutyn E, et al. Immune response to influenza vaccination in a large healthy elderly population. Vaccine 1999 Jan; 17(1): 82–94

    Article  PubMed  CAS  Google Scholar 

  54. Bruunsgaard H, Pedersen M, Pedersen BK. Aging and proinflammatory cytokines. Curr Opin Hematol 2001 May; 8(3): 131–6

    Article  PubMed  CAS  Google Scholar 

  55. Ershler WB, Keller ET. Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Ann Rev Med 2000; 51: 245–70

    Article  PubMed  CAS  Google Scholar 

  56. Mountz JD, Wu J, Zhou T, et al. Cell death and longevity: implications of Fas-mediated apoptosis in T-cell senescence. Immunol Rev 1997 Dec; 160: 19–30

    Article  PubMed  CAS  Google Scholar 

  57. Schwab R, Szabo P, Manavalan JS, et al. Expanded CD4+ and CD8+ T cell clones in elderly humans. J Immunol 1997 May 1; 158(9): 4493–9

    PubMed  CAS  Google Scholar 

  58. Jadoul M, Goubau P. Is anti-hepatitis B virus (HBV) immunization successful in elderly hemodialysis (HD) patients? Clin Nephrol 2002 Oct; 58(4): 301–4

    PubMed  CAS  Google Scholar 

  59. Fabrizi F, Martin P, Dixit V, et al. Meta-analysis: the effect of age on immunological response to hepatitis B vaccine in end-stage renal disease. Aliment Pharmacol Ther 2004 Nov 15; 20(10): 1053–62

    Article  PubMed  CAS  Google Scholar 

  60. Jadoul M, Cornu C, van Ypersele de Strihou C. Incidence and risk factors for hepatitis C seroconversion in hemodialysis: a prospective study. The UCL Collaborative Group. Kidney Int 1993 Dec; 44(6): 1322–6

    Article  PubMed  CAS  Google Scholar 

  61. Jadoul M, Cornu C, van Ypersele de Strihou C. Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The UCL Collaborative Group. Kidney Int 1998 Apr; 53(4): 1022–5

    Article  PubMed  CAS  Google Scholar 

  62. Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 Jul 5; 345(1): 41–52

    Article  PubMed  CAS  Google Scholar 

  63. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet 1981 Mar 7; I(8219): 550–1

    Article  Google Scholar 

  64. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep 2001; 50(RR-5): 1–43

    Google Scholar 

  65. The EBPG Expert Group on Haemodialysis. European best practice guidelines for haemodialysis. Nephrol Dial Transplant 2002; 17Suppl. 7: 72–87

    Google Scholar 

  66. Najem GR, Louria DB, Thind IS, et al. Control of hepatitis B infection: the role of surveillance and an isolation hemodialysis center. JAMA 1981 Jan 9; 245(2): 153–7

    Article  PubMed  CAS  Google Scholar 

  67. Tokars JI, Arduino MJ, Alter MJ. Infection control in hemodialysis units. Infect Dis Clin North Am 2001 Sep; 15(3): 797–812, viii

    Article  PubMed  CAS  Google Scholar 

  68. de Jong GM, de Bruin W, Verresen L, et al. High-flux membranes are not permeable to hepatitis B virus-DNA [letter]. Nephron 1992; 60(3): 368

    Article  PubMed  Google Scholar 

  69. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a high-risk population in the United States. N Engl J Med 1980; 303: 833–41

    Article  PubMed  CAS  Google Scholar 

  70. Köhler H, Arnold WC, Renschin G, et al. Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 1984; 25: 124–8

    Article  PubMed  Google Scholar 

  71. Fabrizi F, Di Filippo S, Marcelli D, et al. Recombinant hepatitis B vaccine use in chronic hemodialysis patients: long-term evaluation and cost-effectiveness analysis. Nephron 1996; 72(4): 536–43

    Article  PubMed  CAS  Google Scholar 

  72. Saab S, Brezina M, Gitnick G, et al. Hepatitis C screening strategies in hemodialysis patients. Am J Kidney Dis 2001 Jul; 38(1): 91–7

    Article  PubMed  CAS  Google Scholar 

  73. Mettang T, Schenk U, Thomas S, et al. Low-dose intradermal versus intramuscular hepatitis B vaccination in patients with end-stage renal failure: a preliminary study. Nephron 1996; 72(2): 192–6

    Article  PubMed  CAS  Google Scholar 

  74. Fabrizi F, Andrulli S, Bacchini G, et al. Intradermal versus intramuscular hepatitis B re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 1997 Jun; 12(6): 1204–11

    Article  PubMed  CAS  Google Scholar 

  75. Vlassopoulos D, Arvanitis D, Lilis D, et al. Complete success of intradermal vaccination against hepatitis B in advanced chronic renal failure and hemodialysis patients. Ren Fail 1997 May; 19(3): 455–60

    Article  PubMed  CAS  Google Scholar 

  76. Charest AF, McDougall J, Goldstein MB. A randomized comparison of intradermal and intramuscular vaccination against hepatitis B virus in incident chronic hemodialysis patients. Am J Kidney Dis 2000 Nov; 36(5): 976–82

    Article  PubMed  CAS  Google Scholar 

  77. Fabrizi F, Lunghi G, Alongi G, et al. Biological dynamics of hepatitis B virus load in dialysis population. Am J Kidney Dis 2003 Jun; 41(6): 1278–85

    Article  PubMed  Google Scholar 

  78. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 Jan 4; 295(1): 65–73

    Article  PubMed  CAS  Google Scholar 

  79. Villeneuve JP, Desrochers M, Infante-Rivard C, et al. A long-term follow-up study of asymptomatic hepatitis B surface antigen-positive carriers in Montreal. Gastroenterology 1994 Apr; 106(4): 1000–5

    PubMed  CAS  Google Scholar 

  80. Josselson J, Kyser BA, Weir MR, et al. Hepatitis B surface antigenemia in a chronic hemodialysis program: lack of influence on morbidity and mortality. Am J Kidney Dis 1987 Jun; 9(6): 456–61

    PubMed  CAS  Google Scholar 

  81. Fornairon S, Pol S, Legendre C, et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation 1996 Jul 27; 62(2): 297–9

    Article  PubMed  CAS  Google Scholar 

  82. Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999 Jan; 29(1): 257–63

    Article  PubMed  CAS  Google Scholar 

  83. Rostaing L, Chatelut E, Payen JL, et al. Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications. J Am Soc Nephrol 1998; 9: 2344–8

    PubMed  CAS  Google Scholar 

  84. Degos F, Pol S, Chaix ML, et al. The tolerance and efficacy of interferon-alpha in haemodialysis patients with HCV infection: a multicentre, prospective study. Nephrol Dial Transplant 2001 May; 16(5): 1017–23

    Article  PubMed  CAS  Google Scholar 

  85. Bohjanen PR, Johnson MD, Szczech LA, et al. Steady-state pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with end-stage renal disease receiving chronic dialysis. Antimicrob Agents Chemother 2002 Aug; 46(8): 2387–92

    Article  PubMed  CAS  Google Scholar 

  86. Ben Ari Z, Broida E, Kittai Y, et al. An open-label study of lamivudine for chronic hepatitis B in six patients with chronic renal failure before and after kidney transplantation. Am J Gastroenterol 2000 Dec; 95(12): 3579–83

    Article  PubMed  CAS  Google Scholar 

  87. Schmilovitz-Weiss H, Melzer E, Tur-Kaspa R, et al. Excellent outcome of lamivudine treatment in patients with chronic renal failure and hepatitis B virus infection. J Clin Gastroenterol 2003 Jul; 37(1): 64–7

    Article  PubMed  CAS  Google Scholar 

  88. Lapinski TW, Flisiak R, Jaroszewicz J, et al. Efficiency and safety of lamivudine therapy in patients with chronic HBV infection, dialysis or after kidney transplantation. World J Gastroenterol 2005 Jan 21; 11(3): 400–2

    PubMed  CAS  Google Scholar 

  89. Garcia A, Mazuecos A, Gonzalez P, et al. Treatment with adefovir dipivoxil in a renal transplant patient with renal insufficiency and lamivudine-resistant hepatitis B infection. Transplant Proc 2005 Apr; 37(3): 1462–3

    Article  PubMed  CAS  Google Scholar 

  90. Fontaine H, Vallet-Pichard A, Chaix ML, et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation 2005 Oct 27; 80(8): 1086–92

    Article  PubMed  CAS  Google Scholar 

  91. European Medicines Agency (EMEA). Hepsera (adefovir dipivoxil): European public assessment report [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/hepsera/hepsera.htm [Accessed 2007 Jan 31]

  92. European Medicines Agency (EMEA). Baraclude (entecavir): European public assessment report [online]. Available from URL: http://www.emea.europa.eu/humandocs/Humans/EPAR/baraclude/baraclude.htm [Accessed 2007 Aug 22]

  93. Spengler U, Nattermann J. Immunopathogenesis in hepatitis C virus cirrhosis. Clin Sci (Lond) 2007 Feb; 112(3): 141–55

    Article  CAS  Google Scholar 

  94. Okuda K, Yokosuka O. Natural history of chronic hepatitis C in patients on hemodialysis: case control study with 4–23 years of follow-up. World J Gastroenterol 2004 Aug 1; 10(15): 2209–12

    PubMed  Google Scholar 

  95. Sterling RK, Sanyal AJ, Luketic VA, et al. Chronic hepatitis C infection in patients with end stage renal disease: characterization of liver histology and viral load in patients awaiting renal transplantation. Am J Gastroenterol 1999 Dec; 94(12): 3576–82

    Article  PubMed  CAS  Google Scholar 

  96. Zylberberg H, Nalpas B, Carnot F, et al. Severe evolution of chronic hepatitis C in renal transplantation: a case control study. Nephrol Dial Transplant 2002 Jan; 17(1): 129–33

    Article  PubMed  Google Scholar 

  97. Lau JY, Davis GL, Brunson ME, et al. Hepatitis C virus infection in kidney transplant recipients. Hepatology 1993 Nov; 18(5): 1027–31

    Article  PubMed  CAS  Google Scholar 

  98. Koenig P, Vogel W, Umlauft F, et al. Interferon treatment for chronic hepatitis C virus infection in uremic patients. Kidney Int 1994 May; 45(5): 1507–9

    Article  PubMed  CAS  Google Scholar 

  99. Pol S, Thiers V, Carnot F, et al. Efficacy and tolerance of alpha2b interferon therapy on HCV infection of hemodialyzed patients. Kidney Int 1995 May; 47(5): 1412–8

    Article  PubMed  CAS  Google Scholar 

  100. Campistol JM, Esforzado N, Martinez J, et al. Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients: pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999 Nov; 14(11): 2704–9

    Article  PubMed  CAS  Google Scholar 

  101. Huraib S, Tanimu D, Romeh SA, et al. Interferon-alpha in chronic hepatitis C infection in dialysis patients. Am J Kidney Dis 1999 Jul; 34(1): 55–60

    Article  PubMed  CAS  Google Scholar 

  102. Izopet J, Rostaing L, Moussion F, et al. High rate of hepatitis C virus clearance in hemodialysis patients after interferon-alpha therapy. J Infect Dis 1997 Dec; 176(6): 1614–7

    Article  PubMed  CAS  Google Scholar 

  103. Okuda K, Hayashi H, Yokozeki K, et al. Interferon treatment for chronic hepatitis C in haemodialysis patients: suggestions based on a small series. J Gastroenterol Hepatol 1995 Sep; 10(5): 616–20

    Article  PubMed  CAS  Google Scholar 

  104. Raptopoulou-Gigi M, Spaia S, Garifallos A, et al. Interferon-alpha 2b treatment of chronic hepatitis C in haemodialysis patients. Nephrol Dial Transplant 1995 Oct; 10(10): 1834–7

    PubMed  CAS  Google Scholar 

  105. Chan TM, Wu PC, Lau JY, et al. Interferon treatment for hepatitis C virus infection in patients on haemodialysis. Nephrol Dial Transplant 1997 Jul; 12(7): 1414–9

    Article  PubMed  CAS  Google Scholar 

  106. Fernandez JL, Rendo P, del Pino N, et al. A double-blind controlled trial of recombinant interferon-alpha 2b in haemodialysis patients with chronic hepatitis C virus infection and abnormal aminotransferase levels: Nephrologists’ Group for the Study of HCV infection. J Viral Hepat 1997 Mar; 4(2): 113–9

    PubMed  CAS  Google Scholar 

  107. Hanrotel C, Toupance O, Lavaud S, et al. Virological and histological responses to one year alpha-interferon-2a in hemodialyzed patients with chronic hepatitis C. Nephron 2001 Jun; 88(2): 120–6

    Article  PubMed  CAS  Google Scholar 

  108. Casanovas-Taltavull T, Baliellas C, Benasco C, et al. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001 Apr; 96(4): 1170–7

    PubMed  CAS  Google Scholar 

  109. Espinosa M, Rodriguez M, Martin-Malo A, et al. Interferon therapy in hemodialysis patients with chronic hepatitis C virus infection induces a high rate of long-term sustained virological and biochemical response. Clin Nephrol 2001 Mar; 55(3): 220–6

    PubMed  CAS  Google Scholar 

  110. Rocha CM, Perez RM, Ferreira AP, et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006 Apr; 26(3): 305–10

    Article  PubMed  CAS  Google Scholar 

  111. Grgurevic I, Vince A, Buljevac M, et al. Efficacy of interferon-alpha in the treatment of chronic hepatitis C in dialysis patients: two therapeutic protocols compared. Nephron Clin Pract 2006; 103(1): c8–11

    Article  PubMed  CAS  Google Scholar 

  112. Covic A, Maftei ID, Mardare NG, et al. Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit. J Nephrol 2006 Nov; 19(6): 794–801

    PubMed  CAS  Google Scholar 

  113. Kokoglu OF, Ucmak H, Hosoglu S, et al. Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C. J Gastroenterol Hepatol 2006 Mar; 21(3): 575–80

    Article  PubMed  CAS  Google Scholar 

  114. Sporea I, Popescu A, Sirli R, et al. Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis. World J Gastroenterol 2006 Jul 14; 12(26): 4191–4

    PubMed  CAS  Google Scholar 

  115. Russo MW, Ghalib R, Sigal S, et al. Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transplant 2006 Feb; 21(2): 437–43

    Article  PubMed  CAS  Google Scholar 

  116. Russmann S, Grattagliano I, Portincasa P, et al. Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr Med Chem 2006; 13(27): 3351–7

    Article  PubMed  CAS  Google Scholar 

  117. Pol S, Vallet-Pichard A, Fontaine H, et al. HCV infection and hemodialysis. Semin Nephrol 2002 Jul; 22(4): 331–9

    PubMed  Google Scholar 

  118. Tan AC, Brouwer JT, Glue P, et al. Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study. Nephrol Dial Transplant 2001 Jan; 16(1): 193–5

    Article  PubMed  CAS  Google Scholar 

  119. Bruchfeld A, Stahle L, Andersson J, et al. Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection: a pilot study. J Viral Hepat 2001 Jul; 8(4): 287–92

    Article  PubMed  CAS  Google Scholar 

  120. Bruchfeld A, Lindahl K, Reichard O, et al. Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients. J Viral Hepat 2006 May; 13(5): 316–21

    Article  PubMed  CAS  Google Scholar 

  121. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998 Oct 31; 352(9138): 1426–32

    Article  PubMed  CAS  Google Scholar 

  122. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C: International Hepatitis Interventional Therapy Group. N Engl J Med 1998 Nov 19; 339(21): 1493–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to assist in the preparation of this review. The author has no conflicts of interest that are directly relevant to the content of this review.

Author information

Authors and Affiliations

  1. Medical Department IV, University of the Saarland, Homburg/Saar, Germany

    Matthias Girndt

Authors
  1. Matthias Girndt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Matthias Girndt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Girndt, M. Viral Hepatitis in Elderly Haemodialysis Patients. Drugs Aging 25, 823–840 (2008). https://doi.org/10.2165/00002512-200825100-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002512-200825100-00002

Keywords

Search

Navigation